Spots Global Cancer Trial Database for overall response rate
Every month we try and update this database with for overall response rate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. | NCT02017457 | Acute Myelogeno... Myelodysplastic... | Donor lymphocyt... Azacytidine | 18 Years - | University Hospital of Mont-Godinne | |
| Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | NCT04350190 | Nasopharyngeal ... | Apatinib mesyla... PD-1 | 18 Years - 70 Years | Guilin Medical University, China | |
| QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma | NCT02383498 | Chordoma | Placebo GI-6301 Vaccine... Radiotherapy wGT3X-BT Actigr... | 18 Years - 100 Years | NantCell, Inc. | |
| Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer | NCT02504892 | Renal Cancer Birt-Hogg-Dube ... | Everolimus | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma | NCT05527795 | Melanoma | Frequency and d... Frequency of ea... Duration of rel... Duration of ove... Overall respons... Frequency of ad... | 18 Years - | Hospices Civils de Lyon | |
| A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients | NCT06277024 | Overall Respons... | Combination of ... | 18 Years - 75 Years | Fujian Medical University | |
| Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma | NCT04899427 | Primary Central... | orelabrutinib Sintilimab Tislelizumab | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC | NCT05670106 | Metastatic Cast... | [177Lu]Lu-PSMA-... Best supportive... 68Ga-PSMA-11 | 18 Years - | Novartis | |
| Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE | NCT01291667 | Progress-free S... Overall Respons... Adverse Events | 18 Years - 70 Years | Shanghai CP Guojian Pharmaceutical Co., Ltd. | ||
| Using Neoantigen Peptide Vaccine/Neoantigen-based DC to Treat Advanced Malignant Solid Tumors | NCT05749627 | Advanced Malign... | Neoantigen pept... Neoantigen-base... | 18 Years - 70 Years | The First Affiliated Hospital of Nanchang University | |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC | NCT05670106 | Metastatic Cast... | [177Lu]Lu-PSMA-... Best supportive... 68Ga-PSMA-11 | 18 Years - | Novartis | |
| Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma | NCT05527795 | Melanoma | Frequency and d... Frequency of ea... Duration of rel... Duration of ove... Overall respons... Frequency of ad... | 18 Years - | Hospices Civils de Lyon | |
| BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT) | NCT02008006 | Follicular Lymp... | BeEAM | 18 Years - 65 Years | Centre Leon Berard | |
| BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT) | NCT02008006 | Follicular Lymp... | BeEAM | 18 Years - 65 Years | Centre Leon Berard | |
| Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma | NCT04899427 | Primary Central... | orelabrutinib Sintilimab Tislelizumab | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma | NCT02383498 | Chordoma | Placebo GI-6301 Vaccine... Radiotherapy wGT3X-BT Actigr... | 18 Years - 100 Years | NantCell, Inc. | |
| A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) | NCT02586857 | Glioblastoma Mu... | ACP-196 | - | Acerta Pharma BV |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
